Cadrenal Therapeutics, Inc. (CVKD) stock
CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.72−0.16 (-8.51%)
Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%
Cadrenal Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cadrenal Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.16M. For fiscal 2025 it was -$12.60M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.60M | – |
| FY2024 | Dec 31, 2024 | -$7.36M | – |
| FY2023 | Dec 31, 2023 | -$3.53M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.23M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.57M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$694.45K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.41M | – |
See a number that looks wrong?